AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19100003 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg (T)
Number of subjects: 345
Study 15723265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid, ASA)
Number of subjects: 0
Study 15723265 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic subjects)
Number of subjects: 0
Study 15723265 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0
Study 11853119 — intervention group
Group type: EXPERIMENTAL
Intervention: bromperidol (6, 12 or 18 mg/day) for 3 weeks
Number of subjects: 30
Study 10486474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 189
Study 10486474 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal dinoprostone
Number of subjects: 189
Study 10486474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol and dinoprostone
Number of subjects: 189
Study 8671503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU HCG (HCG+ group)
Number of subjects: 170
Study 8671503 — intervention group
Group type: COMPARATOR
Intervention: No HCG (HCG‐ group)
Number of subjects: 170
Study 8671503 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG+ group
Number of subjects: 170
Study 8671503 — intervention group
Group type: COMPARATOR
Intervention: HCG‐ group
Number of subjects: 170
Study 1754671 — intervention group
Group type: EXPERIMENTAL
Intervention: Food elimination diet
Number of subjects: 91
Study 1754671 — intervention group
Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 91
Study 1754671 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum IgG levels
Number of subjects: 91
Study 1754671 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test to soy
Number of subjects: 91
Study 1754671 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum or complexed immunoglobulins
Number of subjects: 91
Study 1754671 — intervention group
Group type: COMPARATOR
Intervention: Initial serum immunoglobulin levels
Number of subjects: 91
Study 1754671 — intervention group
Group type: EXPERIMENTAL
Intervention: History of spring/summer exacerbations of eczema
Number of subjects: 91
Study 30039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets alone
Number of subjects: 15
Study 30039387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets containing vitamin C
Number of subjects: 15
Study 28832310 — intervention group
Group type: EXPERIMENTAL
Intervention: DA + SDM
Number of subjects: 329
Study 28832310 — intervention group
Group type: EXPERIMENTAL
Intervention: DA
Number of subjects: 329
Study 28832310 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 329
Study 25243647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 25
Study 25243647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25010824 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy combined with pulsed radiofrequency (PRF) lesioning of the suprascapular nerve (SSN) for 12 weeks.
Number of subjects: 60
Study 25010824 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone for 12 weeks.
Number of subjects: 60
Study 21831230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clove and lemon balm extract
Number of subjects: 120
Study 21831230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clove and agrimony extract
Number of subjects: 120
Study 21831230 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 120
Study 19774311 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (twice a week for 12 weeks)
Number of subjects: 82
Study 19774311 — intervention group
Group type: COMPARATOR
Intervention: Basic care
Number of subjects: 82
Study 17572792 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills education (26-hour competence promotion for students and 5-hour parent training)
Number of subjects: 208
Study 17572792 — intervention group
Group type: COMPARATOR
Intervention: Internal control group
Number of subjects: 208
Study 17572792 — intervention group
Group type: COMPARATOR
Intervention: External control group
Number of subjects: 208
Study 16391401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in SPS
Number of subjects: 50
Study 16391401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in DM
Number of subjects: 50
Study 16391401 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months in SPS
Number of subjects: 50
Study 16391401 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months in DM
Number of subjects: 50
Study 16391401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in IBM
Number of subjects: 50
Study 16391401 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months in IBM
Number of subjects: 50
Study 16391401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in SPS
Number of subjects: 50
Study 16391401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in DM
Number of subjects: 50
Study 12428313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion to maintain controlled hypotension with MAP around 60 mmHg
Number of subjects: 0
Study 12428313 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial blood pressure (MAP) maintained around 80 mmHg (Control Group C)
Number of subjects: 0
Study 9709937 — intervention group
Group type: COMPARATOR
Intervention: Active/Placebo patch (AP group)
Number of subjects: 53
Study 9709937 — intervention group
Group type: COMPARATOR
Intervention: Active/Active patch (AA group)
Number of subjects: 53
Study 9709937 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (PP group)
Number of subjects: 53
Study 8561689 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with OM histories
Number of subjects: 0
Study 8561689 — intervention group
Group type: COMPARATOR
Intervention: Controls (no OM histories)
Number of subjects: 0
Study 2242951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (10 capsules, three times daily)
Number of subjects: 0
Study 2242951 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules (10 capsules, three times daily)
Number of subjects: 0
Study 45195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 9
Study 45195 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 9
Study 45195 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 9
Study 45195 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 9
Study 45195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29781315 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic treatment for Staphylococcus aureus (SA) colonization
Number of subjects: 80
Study 29781315 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 80
Study 29781315 — intervention group
Group type: COMPARATOR
Intervention: Traditional germiculture method
Number of subjects: 80
Study 29781315 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic treatment
Number of subjects: 80
Study 30017459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 30017459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with longitudinal formulation in the first 4 sessions
Number of subjects: 0
Study 27589523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 7 mg/month
Number of subjects: 146
Study 27589523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 2 mg/month
Number of subjects: 146
Study 27589523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 20 mg/month
Number of subjects: 146
Study 27589523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 24449631 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 44
Study 24449631 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 44
Study 22086119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasomatic injections of 4 mg/ml of dexamethasone phosphate followed by vertebroplasty
Number of subjects: 20
Study 22086119 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty alone
Number of subjects: 20
Study 19237497 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat and high coping information
Number of subjects: 254
Study 19237497 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat appraisal information
Number of subjects: 254
Study 17495819 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 50
Study 17495819 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 50
Study 15496046 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (administered within 24 hours of onset of symptoms)
Number of subjects: 0
Study 15496046 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (administered as a nasal gel)
Number of subjects: 0
Study 11170188 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1: Instructed to try to inhibit micturition during bladder filling
Number of subjects: 42
Study 11170188 — intervention group
Group type: COMPARATOR
Intervention: Method 2: Instructed to neither try to void nor inhibit micturition
Number of subjects: 42
Study 11170188 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1
Number of subjects: 42
Study 11170188 — intervention group
Group type: COMPARATOR
Intervention: Method 2
Number of subjects: 42
Study 9554395 — intervention group
Group type: EXPERIMENTAL
Intervention: F-15 scan (furosemide injected 15 minutes before renography)
Number of subjects: 72
Study 9554395 — intervention group
Group type: COMPARATOR
Intervention: F+20 scan (furosemide injected 20 minutes after radiopharmaceutical)
Number of subjects: 72
Study 8276366 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (2 mg, intravenous)
Number of subjects: 21
Study 8276366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml solution, intravenous)
Number of subjects: 21
Study 2657048 — intervention group
Group type: EXPERIMENTAL
Intervention: salsalate (3 g/day, adjusted for efficacy and tolerance)
Number of subjects: 233
Study 2657048 — intervention group
Group type: COMPARATOR
Intervention: aspirin (3.6 g/day, adjusted for efficacy and tolerance)
Number of subjects: 233
Study 4613978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone, 100 mg daily for 14 consecutive days
Number of subjects: 17
Study 4613978 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule for the remaining 56 days
Number of subjects: 17
Study 31072196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 22
Study 31072196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 22
Study 31072196 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 22
Study 28554928 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with patient-controlled epidural administration of ropivacaine and sufentanil combined with standard care
Number of subjects: 148
Study 28554928 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 148
Study 26715476 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine solution applied twice daily after usual oral hygiene care
Number of subjects: 500
Study 26715476 — intervention group
Group type: COMPARATOR
Intervention: Control group with no application after usual oral hygiene care
Number of subjects: 500
Study 23137657 — intervention group
Group type: EXPERIMENTAL
Intervention: LightCycler® SeptiFast (LC‐SF) assay
Number of subjects: 35
Study 23137657 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 35
Study 21190403 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy (CBT)
Number of subjects: 77
Study 18647291 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct technique
Number of subjects: 100
Study 18647291 — intervention group
Group type: COMPARATOR
Intervention: Rotational technique
Number of subjects: 100
Study 16497822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 813
Study 12643970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 80
Study 12643970 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 80
Study 17077660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35% fluorexon disodium and 0.4% benoxinate
Number of subjects: 67
Study 17077660 — intervention group
Group type: COMPARATOR
Intervention: 0.25% sodium fluorescein and 0.4% benoxinate
Number of subjects: 67
Study 17077660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35% fluorexon disodium
Number of subjects: 67
Study 17077660 — intervention group
Group type: COMPARATOR
Intervention: 0.25% sodium fluorescein
Number of subjects: 67
Study 10231452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate iron group (ferric pyrophosphate via hemodialysis at 12 micrograms/dl)
Number of subjects: 21
Study 10231452 — intervention group
Group type: COMPARATOR
Intervention: i.v. iron group (iron dextran)
Number of subjects: 21
Study 10231452 — intervention group
Group type: COMPARATOR
Intervention: i.v. iron group
Number of subjects: 21
Study 10231452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate iron group
Number of subjects: 21
Study 10231452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 8569362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (35.0 [0.5] degrees C)
Number of subjects: 60
Study 8569362 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.6 [0.4] degrees C)
Number of subjects: 60
Study 1945464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylak forte
Number of subjects: 0
Study 1945464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7266633 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antibiotic regimens
Number of subjects: 26
Study 7266633 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 26
Study 31030865 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 0
Study 31030865 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Risk Score (FRS)
Number of subjects: 0
Study 31030865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27557042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 20
Study 27557042 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-formed retainer
Number of subjects: 20
Study 25683972 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose (FCM)
Number of subjects: 459
Study 25683972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 24451151 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg
Number of subjects: 42
Study 24451151 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Number of subjects: 42
Study 24451151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24451151 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg and 60 mg
Number of subjects: 42
Study 23112909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of cholecalciferol (vitamin D(3)) for 3 weeks
Number of subjects: 83
Study 23112909 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 83
Study 18829143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses taught by nurse-instructors (Group A)
Number of subjects: 108
Study 18829143 — intervention group
Group type: COMPARATOR
Intervention: Nurses taught by doctor-instructors (Group B)
Number of subjects: 108
Study 17511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil system (TF group)
Number of subjects: 92
Study 17511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-back technique and lateral condensation (LC group)
Number of subjects: 92
Study 17511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Ethoxybenzoic Acid (sEBA)
Number of subjects: 92
Study 17511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Restorative Material (IRM)
Number of subjects: 92
Study 17511788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 92
Study 17511788 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (n = 12)
Number of subjects: 92
Study 17511788 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (n = 8)
Number of subjects: 92
Study 15304127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography group (n = 34) received additional angiography 1 month after achievement of CN.
Number of subjects: 68
Study 15304127 — intervention group
Group type: COMPARATOR
Intervention: CT group (n = 34) followed using dynamic CT every 3 months without any further intervention.
Number of subjects: 68
Study 15304127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography group (n = 34)
Number of subjects: 68
Study 15304127 — intervention group
Group type: COMPARATOR
Intervention: CT group (n = 34)
Number of subjects: 68
Study 11371741 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.05 mg/kg per day)
Number of subjects: 72
Study 11371741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 9564120 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting opioid medications
Number of subjects: 29
Study 9564120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 29
Study 8034823 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment-based intervention (verbal and written commitments for adherence, tasks to increase investment in medication regimen)
Number of subjects: 0
Study 8034823 — intervention group
Group type: COMPARATOR
Intervention: Control group (performed tasks unrelated to the medical regimen)
Number of subjects: 0
Study 8034823 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 0
Study 28297591 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement (oral 30 µg ethinyl estradiol or transdermal 100 µg 17‐β‐estradiol patch)
Number of subjects: 48
Study 28297591 — intervention group
Group type: COMPARATOR
Intervention: No estrogen (control group)
Number of subjects: 48
Study 25926416 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 802
Study 25926416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 24073532 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based group (Filtek P90/Silorane System Adhesive - 3M ESPE)
Number of subjects: 33
Study 24073532 — intervention group
Group type: COMPARATOR
Intervention: Methacrylate-based group (Filtek P60/Adper SE Plus - 3M ESPE)
Number of subjects: 33
Study 24073532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 33
Study 21612677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece SA60AT IOL
Number of subjects: 51
Study 21612677 — intervention group
Group type: COMPARATOR
Intervention: 3-piece MA60BM IOL
Number of subjects: 51
Study 18155501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 72
Study 18155501 — intervention group
Group type: COMPARATOR
Intervention: Charged coupled device (CCD)
Number of subjects: 72
Study 18155501 — intervention group
Group type: COMPARATOR
Intervention: Photostimulable phosphor plate (PSP)
Number of subjects: 72
Study 17211116 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured drug education program
Number of subjects: 60
Study 17211116 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 12975729 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus and gracilis tendon autografts (ST/G)
Number of subjects: 40
Study 12975729 — intervention group
Group type: COMPARATOR
Intervention: Central third of the patella tendon (BPT)
Number of subjects: 40
Study 10876329 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies‐‐Depression Scale (CES-D)
Number of subjects: 80
Study 9360096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts
Number of subjects: 108
Study 9360096 — intervention group
Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 108
Study 9360096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (Phase II)
Number of subjects: 108
Study 9360096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (overall 7 year follow-up)
Number of subjects: 108
Study 9360096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (fibronectin treated)
Number of subjects: 108
Study 9360096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (above-knee group, fibronectin treated)
Number of subjects: 108
Study 8472827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 12
Study 8472827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pressure support ventilation (NPSV)
Number of subjects: 12
Study 8472827 — intervention group
Group type: COMPARATOR
Intervention: Control night without ventilation
Number of subjects: 12
Study 3513567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg folic acid per day
Number of subjects: 25
Study 3513567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28791887 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdensome condition
Number of subjects: 262
Study 28791887 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 262
Study 28791887 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdensome condition with AS physical concerns
Number of subjects: 262